Ionetix

About:

Ionetix is a pioneering end-to-end radiopharmaceutical provider for cardiac PET imaging.

Website: http://www.ionetix.com

Top Investors: Eli Lilly, Tees River

Description:

Ionetix is engaged in the development, manufacturing, and distribution of a novel class of superconducting cyclotrons for the point-of-care production of PET radioisotopes. With their significantly smaller size, lighter weight, lower power requirement, and lower price point, these systems offer significant advantages over conventional-design cyclotron technology. The company installs, operates, and manages cyclotrons producing the necessary doses of Ammonia N-13 at or near the imaging suite. Ionetix was founded in 2010 and is headquartered in

Total Funding Amount:

$48.8M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

San Francisco, California, United States

Founded Date:

2009-01-01

Contact Email:

info(AT)ionetix.com

Founders:

Timothy Antaya

Number of Employees:

11-50

Last Funding Date:

2024-08-07

IPO Status:

Private

Industries:

© 2025 bioDAO.ai